Regenxbio Inc. appointed Alexandra Glucksmann as a director, effective May 25.
Glucksmann is currently the president and CEO of Cedilla Therapeutics Inc.
Rockville, Md.-based REGENXBIO, is a clinical-stage biotechnology company, which provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease.
